



## Living Cell Technologies Limited

**ACN:** 104 028 042  
**ASX:** LCT  
**OTCQB:** LVCLY

### ASX ANNOUNCEMENT

## LCT Presenting at Gold Coast Investment Showcase

---

### Highlights

- **LCT presenting at Gold Coast Investment Showcase, 22-23 June; COO, Dr Belinda Di Bartolo to update investors from 3.30pm AEST Wednesday, 22 June**
- **Free registration available for investors via this link:**  
**<https://www.eventbrite.com.au/e/gold-coast-investment-showcase-22-23-june-2022-qld-registration-308415638477>**
- **Livestream of presentation available via this link:**  
**<https://www.goldcoastinvestmentshowcase.com.au/livestreamingregistration.html>**

**Sydney, Australia & Auckland, New Zealand - 21 June 2022** – Living Cell Technologies (ASX:LCT) invites investors to attend the Gold Coast Investment Showcase, to be held from 22-23 June at JW Marriott Gold Coast Resort & Spa, Qld.

LCT's Chief Operating Officer, Dr Belinda Di Bartolo, will update investors on the latest progress concerning the Company's potentially groundbreaking research, as LCT advances its third clinical trial of NTCELL in Parkinson's disease.

Investors may register to attend the conference for free via the link below, or alternatively watch the presentation online via the below livestream link.

### Event Details

Date: Wednesday, 22 June 2022 – Thursday 23 June 2022; LCT presentation is from 3.30pm AEST Wednesday, 22 June

Venue: JW Marriott Gold Coast Resort & Spa, 158 Ferny Ave, Surfers Paradise, Qld, 4217

Registration: <https://www.eventbrite.com.au/e/gold-coast-investment-showcase-22-23-june-2022-qld-registration-308415638477>

Livestream link: <https://www.goldcoastinvestmentshowcase.com.au/livestreamingregistration.html>

For more information on the event, please visit <https://www.goldcoastinvestmentshowcase.com.au/>

Authorised for release by the Board of Living Cell Technologies Limited.

– Ends –

**For further information:** [www.lctglobal.com](http://www.lctglobal.com)

<b>At the Company:</b> Bernie Tuch Chief Executive Mobile: +61 411 461 604 <a href="mailto:bernietuch@lctglobal.com">bernietuch@lctglobal.com</a>	<b>For media/investor queries:</b> Anthony Fensom Republic PR Mobile: +61 407 112 623 <a href="mailto:anthony@republicpr.com.au">anthony@republicpr.com.au</a>
---	--

### **About NTCELL**

NTCELL is an alginate coated capsule containing clusters of neonatal porcine choroid plexus cells that are sourced from a unique herd of designated pathogen-free pigs bred from stock originally discovered in the remote sub-Antarctic Auckland Islands. Choroid plexus cells are naturally occurring 'support' cells for the brain and secrete cerebrospinal fluid (CSF), which contains a range of factors that support nerve cell functions and protective enzymes that are crucial for nerve growth and healthy functioning. In NTCELL, the porcine choroid plexus cells are coated with alginate to protect them from attack by the immune system. Therefore, no immunosuppressive regimen needs to be administered to recipients.

### **About Living Cell Technologies**

Living Cell Technologies Limited (ASX: LCT) is an Australasian biotechnology company that is focused on discovering and developing novel treatments for debilitating conditions such as diabetes and Parkinson's disease.

LCT is listed on the Australian (ASX: LCT) and US (OTCQB: LVCLY) stock exchanges. The company is incorporated in Australia, with its operations based in Australia and New Zealand. For more information visit [www.lctglobal.com](http://www.lctglobal.com) or follow @lctglobal on Twitter, Facebook or LinkedIn.

### **Forward-looking statements**

This document may contain certain forward-looking statements, relating to LCT's business, which can be identified by the use of forward-looking terminology such as "promising," "probable", "plans," "anticipated," "will," "project," "believe," "forecast," "expected," "estimated," "targeting," "aiming," "set to," "potential," "seeking to," "goal," "could provide," "intends," "is being developed," "could be," "on track," or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other health authorities' requirements regarding any one or more product candidates, nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialisation of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialise, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. LCT is providing this information and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.